ogesh Kumar Swami
BACKGROUND In India, most of the anti-tuberculosis regimens under Revised National Tuberculosis Control Programme (RNTCP) are rifampicin based. Venous Thrombosis (VT) is a rare side effect of rifampicin and very few cases are reported worldwide. Studies have demonstrated possible association between VT and use of rifampicin, in patients treated with rifampicin containing regimens. MATERIALS AND METHODS This was an observational study done in New Medical College Hospital, Kota during the period June 2016 to July 2018. Careful watch was kept on patients who were admitted for any complications after initiation of ATT. RESULTS During this period, 4 patients, who were taking ATT, presented with thromboembolic events. Mean time of presentation was 71±22 days after starting ATT. 3 patients had lower limb DVT & 1 patient had pulmonary artery thrombus. CONCLUSION Though venous thrombosis is uncommon side effect of rifampicin, treating physicians should be cautious during treatment
